US Patent Issued to Incyte on Sept. 29 for "Anti-tumor combination therapy comprising anti-CD19 antibody and gamma delta T-cells" (German Inventors)

ALEXANDRIA, Va., Sept. 30 -- United States Patent no. 12,747,292, issued on Sept. 29, was assigned to Incyte Corp. (Wilmington, Del.).

"Anti-tumor combination therapy comprising anti-CD19 antibody and gamma delta T-cells" was invented by Jan Endell (Munich), Rainer Boxhammer (Kolbermoor, Germany) and Dominik Pretscher (Wurzburg, Germany).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure is directed to a combination therapy comprising an anti-CD19 antibody or antibody fragment thereof and gamma delta T-cells (GammaDelta T-cells) for use in the treatment of leukemia or lymphoma."

The patent was filed on Oct. 30, 2020, under Application No. 17/084,783.

*For further information, including im...